- Previous Close
184.800 - Open
185.100 - Bid 185.700 x --
- Ask 186.200 x --
- Day's Range
184.000 - 188.700 - 52 Week Range
63.650 - 223.800 - Volume
88,200 - Avg. Volume
489,385 - Market Cap (intraday)
41.427B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.910 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
217.71
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People's Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanlimab), A140, and A400; and non-oncology drug candidates primarily to treat immune-mediated diseases, consisting of rheumatoid arthritis and alopecia areata comprising A223, A277, SKB378, and SKB336. The company has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; and Ellipses Pharma Limited. The company was incorporated in 2016 and is headquartered in Chengdu, the People's Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
kelun-biotech.comRecent News: 6990.HK
View MorePerformance Overview: 6990.HK
Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6990.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6990.HK
View MoreValuation Measures
Market Cap
41.18B
Enterprise Value
38.11B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
20.44
Price/Book (mrq)
11.96
Enterprise Value/Revenue
18.92
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-12.40%
Return on Assets (ttm)
-3.59%
Return on Equity (ttm)
-17.35%
Revenue (ttm)
1.88B
Net Income Avi to Common (ttm)
-186.61M
Diluted EPS (ttm)
-0.910
Balance Sheet and Cash Flow
Total Cash (mrq)
2.89B
Total Debt/Equity (mrq)
1.19%
Levered Free Cash Flow (ttm)
-2.42B